Member Info for Bobat1234

Mms corruption at its best. No wonder many companies leaving.

Heading up from the bottom. 2p incoming

Will be over 2p.

1 million buy printed at 9.5

Unable to get quotes for large amounts

In auction. Mms short of shares.

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Ex-Entitlement Date - Unlisted Redeemable Non-Voting Shares

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Redeemable Non-Voting Shares ("Unlisted RNV Shares") has now passed, its ordinary shares will be marked ex-entitlement in respect of the Unlisted RNV Shares with effect from the commencement of trading today, 1 December 2025.

Accordingly, all holders of ordinary shares and convertible loan notes who were on the Company's register as at close of business on 28 November 2025 will be eligible to receive the Unlisted RNV Shares. In addition, anyone who purchased ordinary shares on Friday, 28 November 2025 will also be eligible to receive the Unlisted RNV Shares.

A detailed timetable for the crediting of the Unlisted RNV Shares to eligible shareholders, together with full details of the entitlement ratio and the exact number of Unlisted RNV Shares to be issued, will be set out in a further announcement to be made in due course.

hxxps://www.**********.com/articles/blencowe-delivers-big-resource-update-and-even-bigger-dfs-8284bfe

Https://www.lse.co.uk/media/BRES/

Updated Corporate Presentation & CEO DFS Interview Links

Blencowe Resources Plc, the natural resources company developing the Orom-Cross graphite project in Uganda, is pleased to announce that it has published an updated corporate presentation incorporating the key outcomes of the recently released Definitive Feasibility Study ("DFS").

The new presentation includes a summary of the DFS results, which confirmed Orom-Cross as a Tier-1 graphite project with US$1.1Bn NPV10, 96% IRR, low capex and world-class margins, as well as details of the integrated downstream USPG facility and a scalable development pathway.

It also highlights the significant further growth potential, with further JORC update expected to incorporate the additional 192 step-out drillholes not included in the DFS already scheduled for early 2026.

The updated presentation is available on the Company's website:

https://blencoweresourcesplc.com/presentation/

The Company also directs shareholders to two recent video interviews with CEO Mike Ralston, in which he discusses the DFS outcomes, the transition into P1 financing, downstream strategy, and the long-term expansion potential:

• Interview 1 - Vox Markets, Blencowe delivers big resource update and even bigger DFS:

https://www.youtube.com/watch?v=gzRsMm62yxA

• Interview 2 - Focus IR, Blencowe releases outstanding DFS for its world-class Orom-Cross graphite mine in Uganda:

https://www.youtube.com/watch?v=7Gkx7nDdceo

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Determination of Record Date and Entitlement

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that, following the announcement on 3 November 2025 regarding the proposed issue of new unlisted redeemable non-voting shares ("Unlisted RNV Shares"), the Company confirms that the record date for determining entitlement to the Unlisted RNV Shares has now passed.

Holders of ordinary shares and convertible loan notes who were on the Company's registers as at close of business on 30 November 2025 (the "Record Date") will be entitled to receive Unlisted RNV Shares.

The Unlisted RNV Shares will carry the right to all future commercial benefits arising from the Company's Midkine Investments portfolio, with the ultimate intention of facilitating an in-specie distribution of the Midkine Investments shares to the holders of Unlisted RNV Shares when the Company's balance sheet permits such a distribution in accordance with the Companies Act 2006.

Full details of the entitlement ratio, the exact number of Unlisted RNV Shares to be issued, the crediting process and the anticipated timetable will be set out in a further announcement to be made in due course.

Regulatory Information

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom d

Bottomsup. Why sell now with all your holding you ould have got all this free shares. But good luck to you. You are always welcome to deramp this now you are out. Looks like we will be seeing you a lot on this chat.

Trades 245

Vol. Sold 4,216,801

Sold Value £96.96k

Vol. Bought 7,409,884

Bought Value £180.66k

Regrets like stress is the big killer.

Lol. I thought you were done. You still here.

Good luck to you. Contract RNs to drop next. This is how aim works

In too. Hopefully RNs out of hours or on Monday to clarify situation.

Peeps selling out on a loss. They should not be trading. Free shares to gain.

Good luck to all the sellers

Feel sorry for peeps who sold out after reading pumpkins messages. Each to their own.